HBVaxPro (hepatitis-B vaccine (rDNA)) / Merck (MSD), Sanofi 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HBVaxPro (hepatitis-B vaccine (rDNA)) / Merck (MSD), Sanofi
2015-000557-21: Efficacy of the vaccine against Hepatitis B in patients under immunosuppressive treatment with past hepatitis B but low antibody titers. Assessment of the usefulness of developing higher antibody titers in the prevention of reactivation of hepatitis B. Eficacia de la vacuna contra el Virus de la Hepatitis B en pacientes inmunosuprimidos con hepatitis B curada pero bajos títulos de anticuerpos. Valoración del desarrollo de títulos más altos de anticuerpos en la prevención de la reactivación de la hepatitis B.

Ongoing
4
100
Europe
Recombinant Hepatitis B surface antigen, Suspension for injection, HBVAXPRO
Vall de Hebron Hospital, Vall de Hebron Hospital
Patients under immunosuppressant therapy with past hepatitis B infection (HBsAg -/antiHBc +) but low antiHBs titers. Pacientes bajo tratamiento inmunosupresor con infección curada por el virus de la hepatitis B (HBsAg -/antiHBc +) pero con títulos bajo de antiHBs., Patients under immunosuppressant therapy with past hepatitis B infection (HBsAg -/antiHBc +) but low antiHBs antibodies. Pacientes bajo tratamiento inmunosupresor con infección curada por el virus de la hepatitis B (HBsAg -/antiHBc +) pero con títulos bajo de anticuerpos contra la infección., Diseases [C] - Virus Diseases [C02]
 
 
2008-001282-28: Influenza, pneumococcal and hepatitis B vaccination in patients with rheumatic autoimmune diseases treated with immunosuppressive therapy

Ongoing
4
200
Europe
Influvac, Pneumovax 23, HBvaxpro
Radboud University Nijmegen Medical Centre
Rheumatic autoimmune diseases including rheumatoid arthritis and poly or dermatomyositis.
 
 
2011-005627-40: Comparison of 4 different Hepatitis B vaccines in healthy persons in whom a standard hepatitis B vaccination schedule of three vaccinations did not induces a protective immune response, so-called non-responders. Vergelijking van 4 verschillende hepatitis B vaccins in gezonde personen die na een standaard serie hepatitis B vaccinaties (3 vaccinaties) geen beschermende afweerreactie hebben opgebouwd, de non-responders.

Ongoing
4
480
Europe
HBVAXPRO, Fendrix, Twinrix, Engerix-B, HBVAXPRO-10, HBVAXPRO-40, Fendrix, Twinrix, Engerix-B, HBVAXPRO-10, HBVAXPRO-40, Fendrix, Twinrix, Engerix-B
previous non-response to hepatitis B vaccine (3 vaccinations, standard schedule) voorheen non-responders op hepatitis B vaccinatie schema (3 vaccinaties, stadaarnd schema)
 
 
2018-002368-18: Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity inimmunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis Bvaccine with increased antigenic load Ensayo clínico de bajo nivel de intervención, de fase IV, para comparar la inmunogenicidaden pacientes inmunosupresores de una vacuna adyuvada contra hepatitis B con unavacuna de elevada carga antigénica

Ongoing
4
740
Europe
Fendrix, HBVAXPRO® 40 micrograms, Fendrix, HBVAXPRO® 40 micrograms, Suspension for injection, Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)., HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR), Beca La Marató 2017 de TV3 (26ª edición)
1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab.2. breast and lung cancer undertreated by chemotherapy3. HIV4. Haematopoietic progenitor cell transplantation (TCPH). 1. Enfermedades reumatológicas autoinmunes en tratamiento con rituximab oinfliximab.2. cáncer de mama y de pulmón en tratamiento con quimioterapia3. VIH4. Trasplantes de células progenitoras hematopoyéticas (TCPH)., 1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab.2. breast and lung cancer undertreated by chemotherapy3. HIV4. Haematopoietic progenitor cell transplantation (TCPH). 1. Enfermedades reumatológicas autoinmunes, cáncer de mama y de pulmón, VIH y trasplantes de células progenitoras hematopoyéticas (TCPH)., Diseases [C] - Immune System Diseases [C20]
 
 
2005-004058-28: A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to that of Aventis Pasteur MSD’s hepatitis B vaccine, HBVAXPRO®, administered according to a 0, 1 months schedule, in pre-dialysis, peritoneal dialysis and haemodialysis patients (above or equal to 15 years of age), who did not respond to previous hepatitis B vaccination.

 
3
100
Europe
Hepatitis B surface antigen, NA, HB-AS02V, NA, HBVAXPRO, HBVAXPRO
Henogen
Female and male pre-dialysis, peritoneal dialysis andhaemodialysis patients with documented evidence of nonresponseto previous hepatitis B vaccination [non-response toprevious hepatitis B vaccination defined as anti-HBs antibodyconcentrations <10 mIU/ml after at least one full course (witha minimum of four injections) of licensed vaccine asindicated for uraemic patients].
 
10/07

Download Options